3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
558
Leukemia
281
Precursor Cell Lymphoblastic Leukemia-Lymphoma
231
Lymphoma
159
Myelodysplastic Syndromes
110
Burkitt Lymphoma
90
Congenital Abnormalities
85
Lymphoma, Non-Hodgkin
84
Leukemia, Monocytic, Acute
83
Leukemia, Myelomonocytic, Acute
81
Lymphoma, Large B-Cell, Diffuse
79
Leukemia, Erythroblastic, Acute
74
Leukemia, Megakaryoblastic, Acute
71
Recurrence
69
Lymphoma, Mantle-Cell
69
Lymphoma, Follicular
48
Leukemia, Myelomonocytic, Chronic
43
Leukemia, Biphenotypic, Acute
43
Hodgkin Disease
43
Lymphoma, Large-Cell, Immunoblastic
36
Blast Crisis
36
Anemia, Refractory, with Excess of Blasts
36
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
35
Leukemia, Lymphocytic, Chronic, B-Cell
32
Myeloproliferative Disorders
30
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
27
Lymphoma, B-Cell, Marginal Zone
23
Leukemia, Myeloid, Chronic-Phase
23
Leukemia, Eosinophilic, Acute
23
Leukemia, Basophilic, Acute
22
Interventions
Cyclophosphamide
13
fludarabine
8
fludarabine phosphate
7
Busulfan
5
Bendamustine Hydrochloride
5
Tacrolimus
4
Rituximab
4
Mycophenolic Acid
4
ibrutinib
3
Melphalan
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
ponatinib
2
pembrolizumab
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
AP 1903 reagent
2
thymoglobulin
1
palbociclib
1
ibritumomab tiuxetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Immune System Diseases
×
Cytarabine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts